Literature DB >> 28634021

Mycoplasma pneumoniae and health outcomes in children with asthma.

Pamela R Wood1, Jordan C Kampschmidt2, Peter H Dube3, Marianna P Cagle3, Paola Chaparro3, Norma S Ketchum4, Thirumalai R Kannan3, Harjinder Singh5, Jay I Peters5, Joel B Baseman3, Edward G Brooks2.   

Abstract

BACKGROUND: Acute infections with Mycoplasma pneumoniae (Mp) have been associated with worsening asthma in children. Mp can be present in the respiratory tract for extended periods; it is unknown whether the long-term persistence of Mp in the respiratory tract affects long-term asthma control.
OBJECTIVE: To determine the effect of Mp on asthma control.
METHODS: We enrolled 31 pediatric subjects 3 to 10 years of age with persistent asthma who completed up to 8 visits over a 24-month period. We detected Mp by antigen capture and polymerase chain reaction. Primary outcome measurements included symptom scores, quality of life, medication scores, oral corticosteroid use, health care usage, school absences, and exhaled breath condensate pH.
RESULTS: Low levels of Mp community-acquired respiratory distress syndrome toxin were detected in 20 subjects (64.5%) at enrollment. Subjects with Mp positivity at a given visit had a .579 probability of remaining Mp positive at the subsequent visit, whereas those with Mp negativity had a .348 probability of becoming Mp positive at the following visit. The incidence of Mp overall was higher in the spring and summer months. Overall, we found no significant relation between the detection of Mp and worse outcome measurements at the same visit or at subsequent visits.
CONCLUSION: The long-term persistence of Mp in the respiratory tract is common in children with asthma. However, the detection of Mp was not associated significantly with worse asthma symptoms, quality of life, health care usage, school absences, or exhaled breath condensate pH in this pediatric asthma cohort.
Copyright © 2017 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28634021      PMCID: PMC5590634          DOI: 10.1016/j.anai.2017.05.022

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  31 in total

1.  Epidemic of Mycoplasma pneumoniae infection in Denmark, 2010 and 2011.

Authors:  S A Uldum; J M Bangsborg; B Gahrn-Hansen; R Ljung; M Mølvadgaard; R Føns Petersen; C Wiid Svarrer
Journal:  Euro Surveill       Date:  2012-02-02

2.  Indoor environmental exposures among children with asthma seen in an urban emergency department.

Authors:  Stephen J Teach; Ellen F Crain; Deborah M Quint; Michelle L Hylan; Jill G Joseph
Journal:  Pediatrics       Date:  2006-04       Impact factor: 7.124

3.  A randomized clinical trial to reduce asthma morbidity among inner-city children: results of the National Cooperative Inner-City Asthma Study.

Authors:  R Evans; P J Gergen; H Mitchell; M Kattan; C Kercsmar; E Crain; J Anderson; P Eggleston; F J Malveaux; H J Wedner
Journal:  J Pediatr       Date:  1999-09       Impact factor: 4.406

4.  Community-acquired pneumonia requiring hospitalization among U.S. children.

Authors:  Seema Jain; Derek J Williams; Sandra R Arnold; Krow Ampofo; Anna M Bramley; Carrie Reed; Chris Stockmann; Evan J Anderson; Carlos G Grijalva; Wesley H Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D Chappell; Robert A Kaufman; J Herman Kan; David Dansie; Noel Lenny; David R Hillyard; Lia M Haynes; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Richard G Wunderink; Kathryn M Edwards; Andrew T Pavia; Jonathan A McCullers; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-02-26       Impact factor: 91.245

5.  Results of molecular detection of Mycoplasma pneumoniae among patients with acute respiratory infection and in their household contacts reveals children as human reservoirs.

Authors:  J W Dorigo-Zetsma; B Wilbrink; H van der Nat; A I Bartelds; M L Heijnen; J Dankert
Journal:  J Infect Dis       Date:  2000-12-27       Impact factor: 5.226

6.  Pathways through which asthma risk factors contribute to asthma severity in inner-city children.

Authors:  Andrew H Liu; Denise C Babineau; Rebecca Z Krouse; Edward M Zoratti; Jacqueline A Pongracic; George T O'Connor; Robert A Wood; Gurjit K Khurana Hershey; Carolyn M Kercsmar; Rebecca S Gruchalla; Meyer Kattan; Stephen J Teach; Melanie Makhija; Dinesh Pillai; Carin I Lamm; James E Gern; Steven M Sigelman; Peter J Gergen; Alkis Togias; Cynthia M Visness; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2016-10       Impact factor: 10.793

7.  ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens.

Authors:  T R Kannan; Joel B Baseman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

8.  Mycoplasma pneumoniae Community Acquired Respiratory Distress Syndrome toxin expression reveals growth phase and infection-dependent regulation.

Authors:  T R Kannan; Oxana Musatovova; Sowmya Balasubramanian; Marianna Cagle; Jarrat L Jordan; Thomas M Krunkosky; Alan Davis; Robert D Hardy; Joel B Baseman
Journal:  Mol Microbiol       Date:  2010-02-28       Impact factor: 3.501

9.  The role of Mycoplasma in upper respiratory infections.

Authors:  Ken B Waites; T Prescott Atkinson
Journal:  Curr Infect Dis Rep       Date:  2009-05       Impact factor: 3.725

10.  Prompting asthma intervention in Rochester-uniting parents and providers (PAIR-UP): a randomized trial.

Authors:  Jill S Halterman; Maria Fagnano; Paul J Tremblay; Susan G Fisher; Hongyue Wang; Cynthia Rand; Peter Szilagyi; Arlene Butz
Journal:  JAMA Pediatr       Date:  2014-10-06       Impact factor: 16.193

View more
  5 in total

1.  Unraveling the Metabolic Routes of Retapamulin: Insights into Drug Development of Pleuromutilins.

Authors:  Feifei Sun; Huiyan Zhang; Gerard Bryan Gonzales; Jinhui Zhou; Yi Li; Jinzhen Zhang; Yue Jin; Zhanhui Wang; Yanshen Li; Xingyuan Cao; Suxia Zhang; Shupeng Yang
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

2.  Morusin alleviates mycoplasma pneumonia via the inhibition of Wnt/β-catenin and NF-κB signaling.

Authors:  Cunrong Chen; Jingjing Wang; Jianfei Chen; Lili Zhou; Hui Wang; Junnian Chen; Zhihui Xu; Shuaijun Zhu; Wei Liu; Ranjie Yu; Junli Lu; Haoteng Luo; Min Chen; Weiwen Chen
Journal:  Biosci Rep       Date:  2019-06-20       Impact factor: 3.840

Review 3.  [Flu-like disease in summer - what do we know about it?]

Authors:  Johannes Bogner
Journal:  MMW Fortschr Med       Date:  2019-06

4.  Fucoxanthin, a Marine Carotenoid, Suppresses Mycoplasma pneumoniae-Triggered Inflammatory Cytokine Production and Promotes Bacterial Clearance in a Murine Model.

Authors:  Hongbo Wu; Shu Li; Linlin Wang; Jun Liang; Lei Yan; Jianjiang Dong
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-21       Impact factor: 2.650

5.  β-Caryophyllene ameliorates the Mycoplasmal pneumonia through the inhibition of NF-κB signal transduction in mice.

Authors:  Mengyao Liu; Wenzhe Niu; Ling Ou
Journal:  Saudi J Biol Sci       Date:  2021-06-17       Impact factor: 4.219

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.